Eledon Pharmaceuticals is a clinical-stage biotech focused on therapies to prevent organ transplant rejection, with no commercial products. Its lead candidate, tegoprubart, recently received FDA orphan drug designation for liver transplantation, enhancing regulatory positioning. The company continues to incur significant operating losses driven by clinical development and finances operations primarily through equity raises, maintaining a solid liquidity buffer but negative free cash flow. Future growth depends heavily on successful clinical milestones, regulatory approvals, and strategic capital allocation amid inherent clinical-stage risks.